Tiziana Life Sciences has developed an investigational technology for the treatment of Covid-19.
The approach involves the use of a handheld inhaler or nebuliser to directly deliver anti-IL-6 receptor (anti-IL-6R) monoclonal antibodies (mAbs) into the lungs.
This is expected to support the company’s development of a fully-human anti-IL6R mAb, TZLS-501, to treat Covid-19.
Tiziana Lifesciences chairman Gabriele Cerrone said: “Direct delivery of anti-IL-6R mAb to the lungs using a portable handheld inhaler or nebuliser is a rapid and immediate therapy for children and adults infected with Covid-19.
“Importantly, this treatment with our fully human anti-IL-6R mAb (TZLS-501) has the potential to be a long-term therapy to halt progression and reduce mortality in patients with Covid-19, as a portion of the population may not opt to utilise a vaccine.”